Schindellegi, Switzerland, June 27th, 2022
Zynnon, a Swiss startup developing a solution to detect the risk of respiratory infection transmission in hospitals and health facilities, has closed a CHF800,000 seed funding round led by a group of angel investors.
Zynnon’s mission is to empower health facilities to improve infection prevention and control. It was born out of the observation that hospital-acquired infections have long been one of the most serious risks for patients, especially those who stay for weeks or months. But recent data show that more than two years into the pandemic, hospitals still have a long way to go to prevent transmission within their premises. With the highly contagious Omicron variant, up to 20% of people hospitalized caught the disease in hospitals.
Zynnon’s solution will monitor the risk of infection transmission in indoor settings in real time using multimodal contactless sensing and cloud-based artificial intelligence. The proposed system will be developed using a cross-field approach combining engineering, data analytics, and medical expertise. The development process will incorporate inputs from clinicians and domain experts, and a pilot study with clinical experts will form the basis for the system’s functional validation.
The funding will enable the company to accelerate the development of its solution and to perform real-world testing in hospitals and health facilities.
“We are delighted to have received so much interest in our venture. With our new investors on board, we can take our passion for building a world-class product to the next level. Thanks to our unique value proposition, our customers will be better equipped to prevent and control the spread of infection within their premises”, explains Khaled Abousaleh, Founder & CEO of Zynnon.
Zynnon (www.zynnon.com) is a startup focused on improving and protecting people’s health using the Internet of Medical Things (IoMT). Zynnon is developing Lieberty, an innovative non-contact multi-parametric sensor combining health and environmental parameters. It is used to analyse indoor spaces in order to evaluate the risk of respiratory infections. The hardware is used in conjunction with our cloud-based artificial intelligence solution, which generates a Risk of Infection Index and provides alerts as well as recommendations for corrective action.
CFO & Investor Relations Manager
+41 79 455 40 30